Newcastle Disease Virus

Overview and Taxonomy of Newcastle Disease Virus

Newcastle disease virus (NDV), synonymous with avian paramyxovirus serotype 1 (APMV-1), represents one of the most significant viral pathogens affecting global poultry production and trade. The virus is the etiological agent of Newcastle disease (ND), a highly contagious and often devastating disease that has been recognized as a notifiable pathogen by the World Organisation for Animal Health (WOAH) for decades [7, 27]. The economic impact of ND is profound, with outbreaks leading to substantial mortality, trade restrictions, and severe losses in both commercial and backyard poultry operations worldwide [1, 12, 28]. Understanding the fundamental biological characteristics and taxonomic framework of NDV is essential for comprehending its pathogenesis, epidemiology, and the development of effective control strategies.

Historical Context and Discovery

The history of NDV is intrinsically linked to the emergence of modern poultry virology. The first recognized outbreaks of what would later be termed Newcastle disease occurred simultaneously in 1926 on the island of Java, Indonesia, and shortly thereafter in Newcastle-upon-Tyne, England [1, 19]. The Indonesian outbreak, reported in the village of Kramat in the Tangerang district, caused catastrophic mortality in native chickens, while the English outbreak was documented by Doyle at the Newcastle-upon-Tyne Veterinary Laboratory [1, 19]. This dual emergence led to the virus being named after the English location, though it is noteworthy that the Indonesian strain was identified first. The virus was subsequently isolated and characterized, and by the mid-20th century, NDV was recognized as a distinct pathogen of the Paramyxoviridae family [19, 27]. The historical significance of these early outbreaks cannot be overstated, as they established ND as a global threat that would require international cooperation for surveillance and control. The virus has since been reported in over 200 avian species, and its distribution is nearly worldwide, with endemic circulation in many parts of Asia, Africa, and the Americas [8, 28].

Taxonomic Classification and Phylogenetic Framework

NDV is classified within the order Mononegavirales, family Paramyxoviridae, subfamily Avulavirinae, and genus Orthoavulavirus [9, 19]. The species is officially designated as Avian orthoavulavirus 1. The virus is a single-stranded, negative-sense, non-segmented RNA virus with a genome of approximately 15,186 nucleotides [19, 24]. The genomic organization is conserved among all NDV strains, consisting of six transcriptional units in the order 3′-NP-P-M-F-HN-L-5′, which encode the nucleoprotein (NP), phosphoprotein (P), matrix protein (M), fusion protein (F), hemagglutinin-neuraminidase (HN), and the large RNA-dependent RNA polymerase (L), respectively [9, 19]. Additionally, the P gene undergoes RNA editing to produce the V and W proteins, which are non-structural proteins involved in interferon antagonism and modulation of host innate immunity [9, 11].

The taxonomic complexity of NDV is considerable, as the virus exists as a single serotype but exhibits extensive genetic diversity [2, 12]. For decades, researchers struggled with inconsistent classification systems that relied on different genetic markers and analytical approaches, leading to confusion in epidemiological studies [2]. In 2019, an international consortium of experts convened to address these discrepancies and established an updated, unified phylogenetic classification system [2]. This consensus system maintains the division of NDV into two major classes: Class I and Class II. Class I viruses are predominantly avirulent and are frequently isolated from wild waterfowl and live bird markets, though they occasionally cause mild disease in poultry [2, 22]. Class II viruses encompass the vast majority of NDV isolates, including all virulent strains responsible for devastating outbreaks in domestic poultry [2, 12].

Within Class II, the updated classification system recognizes 20 distinct genotypes (designated I through XXI, with genotype XV being vacant) based on complete fusion (F) gene sequence analysis, phylogenetic topology, genetic distance thresholds, branch support, and epidemiological independence [2, 20]. The system introduced a dichotomous naming convention for sub-genotypes (e.g., VII.1.1, VII.2) to track viral ancestry and facilitate global comparisons [2]. This framework has been critical for understanding the global molecular epidemiology of NDV, as different genotypes predominate in specific geographic regions and time periods. For example, genotype VII viruses, particularly sub-genotype VII.2 (formerly VIId), have been responsible for the most devastating panzootics in Asia, the Middle East, and Africa since the 1990s [16, 18, 20]. Genotype V viruses, including the newly designated sub-genotype Vd, have been identified in East Africa, underscoring the ongoing evolution of the virus [22]. The continuous emergence of new genotypes and sub-genotypes is driven by the high mutation rate inherent to RNA viruses, coupled with selective pressures from host immunity and vaccination [12, 20].

Virulence Classification and Pathotypes

Beyond genetic classification, NDV isolates are categorized into pathotypes based on their virulence in chickens, a system that is critical for both research and regulatory purposes. The pathotyping system, established by WOAH, relies on standardized in vivo assays: the mean death time (MDT) in embryonated chicken eggs, the intracerebral pathogenicity index (ICPI) in day-old chicks, and the intravenous pathogenicity index (IVPI) in six-week-old chickens [7, 27]. Based on these indices, NDV strains are classified as lentogenic (avirulent or low virulence), mesogenic (intermediate virulence), or velogenic (highly virulent) [19, 28]. Velogenic strains are further subdivided into viscerotropic velogenic (VVNDV), which cause hemorrhagic intestinal lesions, and neurotropic velogenic (NVNDV), which primarily induce neurological signs and respiratory distress [27, 28]. Lentogenic strains, such as LaSota and B1, are widely used as live attenuated vaccines due to their safety profile and ability to induce protective immunity [7, 20]. Mesogenic strains, such as Roakin and Mukteswar, have been used historically as booster vaccines in some regions, but their use has declined due to concerns about residual pathogenicity [24].

The molecular basis for virulence is primarily determined by the amino acid sequence at the fusion protein cleavage site (F0) [23, 27]. The F0 protein must be cleaved by host cell proteases into the disulfide-linked F1 and F2 subunits for the virus to become infectious. Lentogenic strains possess a monobasic cleavage site (e.g., (^{112})G-G-R-Q-G-R-L(^{117})), which is recognized only by trypsin-like proteases found in the respiratory and intestinal tracts, limiting replication to these sites [23, 27]. In contrast, velogenic and mesogenic strains contain a polybasic cleavage site (e.g., (^{112})R-R-Q-K-R-F(^{117}) or (^{112})R-R-R-K-R-F(^{117})), which is cleavable by ubiquitous furin-like proteases present in virtually all tissues, enabling systemic dissemination and severe disease [23, 27]. However, the cleavage site is not the sole determinant of virulence; additional regions within the F protein, as well as contributions from the HN protein and other viral genes, modulate pathogenicity [23, 29]. For instance, studies have shown that chimeric viruses containing the F protein from a mesogenic pigeon paramyxovirus-1 (PPMV-1) strain in a lentogenic backbone exhibit variable ICPIs depending on which specific regions of the F protein are exchanged, indicating that structural domains beyond the cleavage site influence fusogenicity and virulence [23].

Genomic and Structural Features

The NDV genome is encapsidated by the nucleoprotein (NP) to form a helical ribonucleoprotein complex (RNP), which serves as the template for transcription and replication [9, 19]. The phosphoprotein (P) acts as a cofactor for the RNA-dependent RNA polymerase (L), while the matrix protein (M) orchestrates viral assembly and budding [9]. The two surface glycoproteins, the hemagglutinin-neuraminidase (HN) and the fusion (F) protein, are the primary targets of the host immune response and are critical for viral entry [27, 29]. The HN protein mediates attachment to sialic acid-containing receptors on host cells and possesses neuraminidase activity, which facilitates viral release [15, 30]. The F protein mediates the fusion of the viral envelope with the host cell membrane, a process that can occur at the plasma membrane or via endocytosis depending on the strain and cell type [30]. Recent evidence indicates that NDV entry is not limited to direct fusion at the plasma membrane; a significant proportion of virus particles enter cells through dynamin-dependent, low pH-triggered endocytosis, a pathway that may be particularly important for infection in certain cell types [30].

The HN protein also plays a pivotal role in determining viral thermostability, a property of considerable practical importance for vaccine development in regions with limited cold chain infrastructure [15]. Studies have demonstrated that the thermostability of NDV is primarily conferred by the HN protein, and exchanging the HN gene from a thermostable strain (e.g., TS09-C) into a thermolabile vaccine backbone (e.g., LaSota) yields a chimeric virus with enhanced thermal resistance [15]. This finding has direct implications for the design of next-generation vaccines suitable for use in resource-limited settings.

Epidemiology and Host Range

NDV has an exceptionally broad host range, infecting over 250 species of birds across 27 orders [8, 28]. Galliform birds (chickens, turkeys, quail) are the most susceptible, with velogenic strains causing mortality rates approaching 100% in naïve flocks [27, 28]. Waterfowl, such as ducks and geese, are generally considered natural reservoirs of lentogenic and mesogenic strains, often exhibiting subclinical infections while shedding virus into the environment [17, 25]. However, the emergence of velogenic strains capable of causing disease in ducks has been documented, challenging the traditional view of ducks as resistant carriers [25]. The 2018-2019 outbreak of virulent NDV in California, which affected 401 backyard and four commercial flocks, as well as one live bird market, demonstrated that the virus can efficiently transmit among backyard poultry and spill over into commercial operations, highlighting the importance of surveillance in non-commercial settings [10].

Live bird markets (LBMs) are recognized as critical nodes in the epidemiology of NDV, serving as reservoirs for virulent strains and facilitating the mixing of multiple genotypes [22, 26]. Studies in Uganda and Ethiopia have isolated velogenic NDV from apparently healthy birds in LBMs, indicating that subclinical carriers can perpetuate viral circulation [22, 26]. The role of co-infections with other avian pathogens, such as avian influenza virus (AIV) and infectious bronchitis virus (IBV), further complicates the epidemiological picture. Experimental co-infections of ducks with virulent NDV and low or highly pathogenic AIV have shown that co-infection can alter virus shedding dynamics, transmission rates, and disease severity, with the timing of infection being a critical determinant [17]. Similarly, co-infections in chickens with lentogenic NDV and low pathogenicity AIV can lead to virus interference, reducing the replication of one or both viruses [21]. These interactions underscore the need for integrated surveillance strategies that account for the polymicrobial nature of respiratory disease in poultry.

Zoonotic Potential and Public Health Significance

NDV is not considered a significant zoonotic pathogen, as it is highly host-range restricted and does not efficiently replicate in mammalian cells [6, 13]. However, human infections have been reported sporadically, typically in individuals with direct and intensive exposure to infected birds or laboratory workers handling concentrated virus [6, 14]. Clinical manifestations in humans are generally mild and self-limiting, most commonly presenting as unilateral or bilateral conjunctivitis, sometimes accompanied by preauricular lymphadenopathy, headache, and malaise [6, 14]. No human-to-human transmission has been documented, and the virus poses no public health threat in the context of food safety [6]. The lack of pre-existing immunity to NDV in the human population, combined with its excellent safety profile, has made NDV an attractive platform for vaccine vector development and oncolytic virotherapy [3, 4, 6, 13]. Recombinant NDV vectors expressing heterologous antigens, such as the spike protein of SARS-CoV-2, have shown remarkable immunogenicity and protective efficacy in preclinical models, and are being advanced as cost-effective vaccine candidates that can be manufactured using existing influenza vaccine production infrastructure [3-5].

In conclusion, the overview and taxonomy of Newcastle disease virus reveal a pathogen of immense complexity and global significance. From its initial identification in 1926 to the sophisticated phylogenetic frameworks of today, NDV continues to challenge our understanding of viral evolution, host-pathogen interactions, and disease control. The unified classification system established in 2019 provides a robust foundation for future epidemiological studies and vaccine development, while the ongoing emergence of new genotypes underscores the need for sustained surveillance and adaptive control strategies. The dual nature of NDV as both a devastating agricultural pathogen and a promising therapeutic vector exemplifies the intricate relationship between viruses and their hosts, and highlights the importance of continued research into this remarkable virus.

Molecular Pathogenesis and Virulence Determinants of NDV

The pathogenic capacity of Newcastle disease virus (NDV) is a multifaceted phenomenon orchestrated by a complex interplay between viral genetic determinants and host cellular responses. The molecular basis of NDV virulence is not solely attributable to a single genetic element but rather emerges from the coordinated functions of multiple viral proteins, primarily the fusion (F) glycoprotein, the hemagglutinin-neuraminidase (HN) protein, the phosphoprotein (P) gene products including V and W proteins, and the matrix (M) protein, which collectively dictate tissue tropism, replication efficiency, immune evasion, and cytopathogenicity [19, 31]. Understanding these molecular mechanisms is paramount for elucidating the continuum from subclinical lentogenic infection to the devastating velogenic disease that commands immediate notification to the World Organisation for Animal Health (WOAH) and results in severe economic repercussions for the global poultry industry [1, 8, 28].

The Fusion Protein Cleavage Site: The Cardinal Determinant of Virulence

The F protein is synthesized as an inactive precursor, F0, which must be cleaved by host cell proteases to yield the fusogenic F1 and F2 subunits. This proteolytic activation is essential for viral entry and cell-to-cell spread, and the amino acid sequence at the cleavage site constitutes the single most critical molecular determinant of NDV pathotype [19, 24, 31]. Lentogenic (low-virulence) strains possess a monobasic cleavage site motif (e.g., ¹¹²GGRQGR↓L¹¹⁷), which is cleaved only by trypsin-like proteases found exclusively in the respiratory and intestinal tracts, thereby restricting infection to these mucosae [19, 23]. In stark contrast, velogenic (highly virulent) and mesogenic (intermediate-virulence) strains harbor a polybasic motif (e.g., ¹¹²RRQKRF¹¹⁷ or ¹¹²RRRKGF¹¹⁷), which is recognized and cleaved by ubiquitous furin-like proteases present in virtually all tissues [16, 24, 31]. This systemic cleavability enables the virus to disseminate throughout the host, causing the severe vascular, neurological, and gastrointestinal pathology characteristic of velogenic Newcastle disease (ND) [10, 18].

While the polybasic cleavage site is a prerequisite for high virulence, it is not sufficient in isolation. Groundbreaking studies by Heiden et al. (2014) demonstrated that exchanging the entire F protein gene from a mesogenic pigeon paramyxovirus-1 (PPMV-1) isolate (with an ICPI of 1.1 and a polybasic R-R-K-K-R↓F motif) into the backbone of the lentogenic NDV Clone 30 strain yielded a recombinant virus with an ICPI of only 0.6, classifying it as lentogenic [23]. Conversely, directly mutating the lentogenic Clone 30 cleavage site (G-R-Q-G-R↓L) to the polybasic R-R-K-K-R↓F motif resulted in a recombinant virus with a markedly elevated ICPI of 1.36, surpassing the virulence of the original PPMV-1 donor [23]. These experiments unequivocally reveal that other regions within the F protein, including the heptad repeat domains and the transmembrane domain, significantly modulate the fusogenic activity and overall pathogenic potential imparted by the polybasic cleavage site [23]. The F protein is also the primary driver of protective immunity, and genotype-matched vaccines incorporating the F protein from circulating velogenic strains have demonstrated superior efficacy in reducing viral shedding compared to traditional vaccines based on heterologous genotype II strains [29].

The Hemagglutinin-Neuraminidase Protein: Receptor Specificity, Immune Evasion, and Thermostability

The HN glycoprotein executes dual enzymatic functions, hemagglutinin (receptor-binding) and neuraminidase (receptor-destroying) activities, which are essential for viral attachment to sialic acid-containing receptors on host cells and for the release of progeny virions [19, 27]. The HN protein also facilitates the fusion-promoting activity of the F protein through a specific interaction that lowers the activation energy for membrane merger [30, 31]. The length of the HN protein's C-terminal extension has been correlated with virulence; velogenic isolates often exhibit a shorter stalk region compared to lentogenic strains, although this is not an absolute rule [16]. Beyond its role in entry, the HN protein is a major antigenic target for neutralizing antibodies, and antigenic drift in HN, particularly at neutralizing epitopes, has been implicated in vaccine escape. Studies of emerging genotype VIId isolates in China revealed multiple amino acid substitutions in major neutralizing epitopes of the HN and F proteins, correlating with the failure of the LaSota vaccine (genotype II) to fully protect against challenge [18]. This antigenic variation underscores the dynamic evolution of NDV and the necessity for continuous surveillance and vaccine updating [2, 20].

Interestingly, the HN protein has also been identified as the key determinant of NDV thermostability. Using reverse genetics to exchange the HN gene between the thermostable TS09-C strain and the thermolabile LaSota strain, Wen et al. (2016) demonstrated that chimeric viruses bearing the TS09-C HN protein exhibited a thermostable phenotype, whereas those with the LaSota HN were thermolabile [15]. Both the hemagglutinin and neuraminidase activities of the TS09-C HN were significantly more resistant to thermal inactivation, and a recombinant virus expressing this HN in a LaSota backbone provided superior antibody responses and complete protection against challenge [15]. This finding has profound implications for vaccine development in resource-limited settings where cold chain maintenance is problematic.

The V and W Proteins: Multifunctional Antagonists of the Host Innate Immune Response

NDV encodes several accessory proteins from the P gene via a process of RNA editing, in which the viral polymerase inserts non-templated guanine residues during transcription [11, 31]. The phosphoprotein (P) is the primary transcript, while the addition of one or two G residues yields the V and W proteins, respectively. These proteins share a common N-terminal domain with P but possess unique C-terminal domains that confer distinct functions. The V protein is a potent antagonist of the host type I interferon (IFN) response. It achieves this through multiple mechanisms, including the inhibition of signal transducer and activator of transcription (STAT) protein phosphorylation, the degradation of STAT1, and the suppression of melanoma differentiation-associated protein 5 (MDA5), a key cytosolic sensor for viral RNA [6, 31]. By crippling the IFN signaling cascade, V protein creates a permissive environment for viral replication and spread, and its activity is a major determinant of virulence. Lentogenic strains typically express a functionally robust V protein, while some highly virulent strains may have mutations that alter its anti-IFN capacity, suggesting that the interplay between V protein function and F protein cleavability is a critical balancing act in NDV pathogenesis [31].

The W protein, whose expression was definitively confirmed only recently by Karsunke et al. (2019), adds another layer of complexity to NDV-host interactions [11]. Using W-specific antisera, this study demonstrated that W protein is expressed during NDV infection and, remarkably, is incorporated into viral particles. Confocal microscopy revealed that W protein accumulates in the nucleus, a property attributable to a bipartite nuclear localization sequence (NLS) within its unique C-terminal domain [11]. Mutation of this NLS confirmed its functionality, causing redistribution of W to the cytoplasm [11]. The nuclear localization of W suggests it may have functions distinct from the cytoplasmic V and P proteins, potentially interfering with host cell transcription, splicing, or DNA damage responses. This discovery opens new avenues for investigating how W protein contributes to the overall pathogenic program of NDV, particularly in modulating the host cell nucleus to favor viral replication.

Host-Virus Interplay: Induction of Cellular Stress, Metabolic Reprogramming, and Immunopathology

NDV infection triggers a complex and often contradictory cascade of host cellular responses, including the unfolded protein response (UPR), autophagy, apoptosis, mitophagy, and ferroptosis. The virus exploits these pathways to facilitate replication while simultaneously inducing the tissue damage characteristic of clinical disease.

Li et al. (2019) demonstrated that NDV infection activates all three arms of the UPR, PERK-eIF2α, ATF6, and IRE1α, in both avian cells and human cancer cell lines [34]. The PERK-eIF2α pathway leads to the translational induction of the transcription factor CHOP, which then suppresses anti-apoptotic BCL-2 and MCL-1 while activating pro-apoptotic JNK signaling. Simultaneously, IRE1α splices XBP1 mRNA, producing the active transcription factor XBP1s, which upregulates ER chaperones and ER-associated degradation (ERAD) components [34]. Crucially, suppression of either apoptosis or UPR signaling impaired NDV proliferation, indicating that the virus co-opts these stress responses for its own benefit [34]. The IRE1α-JNK axis also promotes the secretion of inflammatory cytokines, contributing to the cytokine storm that drives systemic disease [34, 35].

At the metabolic level, NDV profoundly rewires cellular energy metabolism through the induction of PINK1-PRKN-dependent mitophagy. Gong et al. (2021) showed that NDV infection causes mitochondrial damage, increased mitochondrial reactive oxygen species (mROS), and electron transport chain dysfunction [32]. The resulting energy deficit elevates the AMP:ATP ratio, activating AMPK and triggering autophagy. The virus then selectively targets mitochondria for degradation via mitophagy, leading to the loss of the NAD+-dependent deacetylase SIRT3. This loss in turn stabilizes HIF1A, driving a metabolic switch from oxidative phosphorylation (OXPHOS) to aerobic glycolysis, the Warburg effect, which provides the biosynthetic precursors necessary for viral replication [32]. This metabolic hijacking is a hallmark of NDV pathogenesis and contributes to the cellular damage observed in infected tissues.

Furthermore, Kan et al. (2021) discovered that NDV can induce ferroptosis, an iron-dependent form of non-apoptotic cell death, in tumor cells [33]. This occurs through the p53-SLC7A11-GPX4 pathway, leading to the accumulation of lipid peroxides. The virus also promotes ferritinophagy, the autophagic degradation of ferritin, which releases labile iron and amplifies the Fenton reaction, driving further lipid peroxidation and cell death [33]. The induction of multiple, overlapping cell death pathways (apoptosis, necrosis, autophagy, and ferroptosis) underscores the multimodal oncolytic action of NDV but also explains the extensive tissue necrosis observed in velogenic infections [33, 39].

The Inflammatory Response: A Double-Edged Sword in Pathogenesis

The clinical severity of NDV infection is largely a consequence of the dysregulated host inflammatory response. Virulent NDV strains induce a massive release of pro-inflammatory cytokines, including IL-6, IFN-γ, and particularly IL-1β, which is the central mediator of the inflammatory fever and acute-phase response [31, 35, 36]. Gao et al. (2020) elucidated the mechanism by which NDV RNA triggers IL-1β expression through the NLRP3/caspase-1 inflammasome. Viral RNA alone was sufficient to activate this pathway, and inhibition of NLRP3 or caspase-1 significantly reduced IL-1β levels [35]. Importantly, neutralization of IL-1β with specific antibodies reduced fever and mortality in infected chickens, demonstrating a direct causal link between inflammasome activation and disease severity [35].

Another key damage-associated molecular pattern (DAMP) implicated in NDV pathogenesis is high mobility group box 1 (HMGB1). Qu et al. (2018) reported that NDV infection triggers the release of HMGB1 from both avian DF-1 cells and human A549 cells [38]. Extracellular HMGB1 acts through its cognate receptors, RAGE, TLR2, and TLR4, to amplify NF-κB activation and the production of multiple inflammatory cytokines, contributing to the "cytokine storm." Neutralization of HMGB1 in vivo significantly increased chicken survival and reduced pathological lesions and inflammatory gene expression [38]. These findings highlight the potential of targeting the host inflammatory response, rather than the virus itself, as a therapeutic strategy for severe Newcastle disease.

Epidemiological and Evolutionary Implications for Virulence

The remarkable genetic diversity of NDV, currently classified into two classes (I and II) and at least 20 genotypes, has profound implications for pathogenesis and disease control [2, 20]. The continuous emergence of new genotypes and sub-genotypes, driven by the high mutation rate of the RNA-dependent RNA polymerase and frequent recombination events, can result in antigenic variants that evade vaccine-induced immunity [2, 12, 18]. The 2018-2019 California outbreak, caused by a virulent NDV closely related to isolates from 2002 and from Belize in 2008, demonstrated that despite decades of genetic drift, the fundamental pathogenic properties of velogenic strains remain highly conserved; all three viruses caused 100% mortality in challenged chickens and efficiently transmitted to contact birds [10]. This phenotypic stability, despite genotypic divergence, underscores the robustness of the polybasic cleavage site and other core virulence determinants.

Furthermore, the host range and reservoir status of different species add complexity to NDV epidemiology. While chickens are highly susceptible to velogenic strains, ducks are often considered resistant reservoirs. However, Dai et al. (2014) demonstrated that duck-origin virulent NDV can cause clinical disease and mortality in ducks, particularly in young birds and certain breeds (e.g., Mallards), and that infected ducks shed infectious virus for up to seven days [25]. This confirms that waterfowl are not merely passive carriers but can serve as active amplifiers and transmitters of virulent NDV, complicating eradication efforts in regions with free-range duck production [25]. Co-infections with other pathogens, such as avian influenza virus or Mycoplasma gallisepticum, further modulate NDV pathogenesis. Co-infection with a low pathogenic avian influenza virus (LPAIV) in ducks significantly reduced NDV shedding, suggesting viral interference, while co-infection with highly pathogenic avian influenza (HPAIV) reduced survival times [17]. These interactions highlight the need to consider the polymicrobial context when assessing NDV virulence in the field [17, 21, 37].

In summary, the molecular pathogenesis of NDV is a hierarchical and integrated process. The polybasic F cleavage site is the master switch that unlocks systemic infection, but the magnitude of the resulting disease is shaped by the efficiency of HN-mediated attachment and fusion, the potency of V/W-mediated interferon antagonism, the metabolic reprogramming orchestrated by mitophagy, and the unleashing of a damaging inflammatory cascade. The continued evolution of NDV, particularly in regions with intensive poultry production and incomplete vaccine coverage, ensures that a deep understanding of these molecular determinants will remain essential for designing effective control strategies, including next-generation genotype-matched vaccines and antiviral therapeutics that target specific host-virus interfaces.

Epidemiology, Global Distribution, and Genotypic Diversity of NDV

Newcastle disease virus (NDV), a non-segmented, negative-sense single-stranded RNA virus belonging to the family Paramyxoviridae and genus Avulavirus, continues to represent one of the most significant threats to global poultry production, food security, and rural livelihoods. As a pathogen listed by the World Organisation for Animal Health (WOAH), NDV is subject to immediate mandatory reporting, underscoring its profound socioeconomic and trade-related consequences. The epidemiological landscape of NDV is characterized by dynamic cycles of emergence, sustained endemicity in several continents, and a remarkable genotypic plasticity that challenges conventional control strategies.

Global Burden and Transmission Dynamics

The disease was first recognized contemporaneously in 1926 on the island of Java, Indonesia, and in Newcastle-upon-Tyne, England, lending the virus its common name [1, 28]. Over the subsequent century, NDV has disseminated globally, establishing endemic circulation in much of Asia, Africa, and parts of the Americas. According to WOAH and Food and Agriculture Organization (FAO) surveillance frameworks, NDV remains a persistent constraint to poultry productivity, particularly in low- and middle-income countries where backyard and smallholder systems predominate [20, 28]. The virus is capable of infecting over 200 avian species, though its clinical and economic impact is most severe in domestic chickens (Gallus gallus domesticus) [8, 19]. Transmission occurs predominantly via the fecal-oral and respiratory routes, with contaminated feed, water, equipment, and human fomites serving as efficient mechanical vectors [28]. The high density of birds in commercial operations, coupled with the presence of live bird markets (LBMs), creates an epidemiological nexus that facilitates rapid viral amplification and geographic spread. Indeed, studies from Ethiopia and Uganda have demonstrated that clinically healthy poultry traded in LBMs can harbor virulent NDV strains, serving as silent reservoirs and seeding outbreaks in naïve flocks [22, 26].

Pathotype Classification and Virulence Determinants

NDV isolates are historically classified into three major pathotypes based on their virulence in chickens: lentogenic (low virulence), mesogenic (intermediate virulence), and velogenic (high virulence). Velogenic strains, which can cause mortality rates approaching 100% in unprotected flocks, are further subdivided into viscerotropic (predominantly hemorrhagic gastrointestinal lesions) and neurotropic (primarily neurological signs) variants [19, 23, 31]. The molecular basis for this virulence spectrum is largely, though not exclusively, determined by the amino acid sequence at the fusion (F) protein cleavage site. Lentogenic strains possess a monobasic cleavage site (e.g., (^{112}\text{GGRQGRL}^{117})), which is cleaved only by trypsin-like proteases present in the respiratory and gastrointestinal tracts, thus restricting replication to these tissues. In contrast, mesogenic and velogenic strains harbor a polybasic motif (e.g., (^{112}\text{RRQKRF}^{117}) or (^{112}\text{RRRKRF}^{117})), which is recognized by ubiquitous furin-like proteases, permitting systemic viral dissemination and severe multiorgan pathology [23, 24, 31]. However, the F cleavage site is not the sole determinant of virulence. Heiden et al. (2014) demonstrated through reverse genetics that chimeric viruses containing the F protein from a mesogenic pigeon paramyxovirus-1 (PPMV-1) within a lentogenic Clone 30 backbone exhibited an intracerebral pathogenicity index (ICPI) of only 0.6, whereas exchanging the cleavage site alone to a polybasic motif in Clone 30 yielded an ICPI of 1.36, higher than the parental PPMV-1 [23]. These findings indicate that other regions of the F protein, along with contributions from the hemagglutinin-neuraminidase (HN) protein and the viral polymerase complex, modulate pathogenic potential in a strain-specific manner [23, 30, 31].

Genotypic Diversity and the Unified Classification System

The genetic diversity of NDV has historically been a source of taxonomic confusion, with multiple overlapping classification systems hindering comparative epidemiological analyses. In 2019, an international consortium of experts established an updated, unified phylogenetic classification system that is now the global standard [2]. This system maintains two major divisions, class I and class II, originally defined based on genomic differences. Class I viruses are predominantly avirulent, are frequently isolated from waterfowl and live bird markets, and are classified into a single genotype (genotype 1) with several sub-genotypes [2, 19]. Class II viruses encompass the vast majority of NDV diversity and include all virulent strains responsible for major outbreaks. The current consensus recognizes a total of 20 genotypes (I–XXI, with genotype XV now considered obsolete) within class II, each defined by objective genetic distance thresholds (nucleotide divergence >10% based on the complete F gene coding sequence), robust branch support in maximum-likelihood and Bayesian phylogenies, and epidemiological independence [2, 19, 20]. Sub-genotypes are denoted using a dichotomous naming system (e.g., VIId, VIf) to track ancestry, and the consortium provides curated datasets and rigorous guidelines for consistent assignment across laboratories [2].

This genotypic framework has illuminated profound spatiotemporal patterns. Early genotypes (I, II, III, IV) were associated with the initial pandemics of the 1920s–1970s and are now rarely found in the field, having been largely supplanted by more recent lineages [2, 19, 24]. Genotype II, however, remains critically important because it includes the widely used vaccine strains LaSota, B1, and F, which were isolated over 70 years ago [7, 18, 24, 42]. From the 1990s onward, genotype V (particularly sub-genotype Vd in East Africa) and especially genotype VII (sub-genotypes VIId, VIIe, VIIj, VIIk, and VIIl) have become globally dominant, emerging as the primary causal agents of epizootics in Asia, the Middle East, Africa, and parts of Europe [2, 18-20]. Genotype VII strains, often referred to as the "newly emerging" or "pandemic" genotype, are characterized by a high degree of antigenic variation from vaccine strains and have been repeatedly isolated from vaccinated flocks, suggesting immune evasion or insufficient vaccine-induced protection [16, 18, 20, 36].

Regional Epidemiological Patterns

The distribution of NDV genotypes varies considerably by geographic region, reflecting historical introduction events, trade networks, and local ecological factors. Asia, particularly China and Southeast Asia, represents an epicenter of NDV genetic diversity and emergence. In China, the predominant circulating strains since the late 1990s belong to sub-genotype VIId, and these viruses have been implicated in repeated outbreaks in vaccinated chicken populations. Wang et al. (2015) characterized nine velogenic isolates from Shaanxi Province in northwestern China, all containing the virulent cleavage site motif (^{112}\text{RRQKRF}^{117}) and exhibiting amino acid substitutions at critical neutralizing epitopes on both the F and HN proteins [18]. These substitutions contributed to a vaccine efficacy failure, whereby LaSota-vaccinated specific-pathogen-free (SPF) chickens were not fully protected against challenge [18]. Similarly, in Malaysia, a genotype VII isolate (IBS002) with an ICPI of 1.76 was recovered from a commercial broiler farm despite routine vaccination with LaSota, and genotype-matched vaccines were significantly more effective at reducing viral shedding than the heterologous LaSota vaccine [16]. Indonesia, where NDV was first described, remains hyperendemic, with dynamic viral evolution necessitating ongoing updates to vaccine and diagnostic strategies [1].

In Africa, the epidemiological picture is dominated by a complex mosaic of genotypes V, VI, VII, and XVIII, often with high genetic distances from vaccine strains [12, 20, 28]. In Nigeria, molecular characterization has revealed the co-circulation of multiple genotypes, including a novel genotype XVIII, and the wide divergence between field isolates and the commonly used LaSota and Komarov vaccines (genotype II) [12]. This genetic mismatch is believed to be a major contributor to recurrent ND outbreaks in both commercial and village poultry. In Ethiopia, surveillance in LBMs in Addis Ababa identified virulent sub-genotype VIf strains in 29 of 146 positive samples, coupled with exceptionally poor biosecurity practices among traders [26]. In Uganda, Byarugaba et al. (2014) isolated velogenic genotype Vd strains from apparently healthy birds in LBMs, confirming that these markets serve as reservoirs and amplifiers of highly virulent virus capable of causing devastating outbreaks in backyard free-range systems [22].

In the Americas, the situation is different but no less challenging. The United States experienced a significant exotic NDV (END) outbreak in southern California from May 2018 through 2019, affecting 401 backyard flocks, four commercial premises, and one live bird market, with spillover into Utah [10]. The causative virus, while not genetically identical to prior strains, was phenotypically similar to the 2002 California END virus and the 2008 Belize virus, exhibiting high virulence across all age groups and efficient transmission via direct contact [10]. The outbreak was ultimately controlled through a combination of strict quarantine, depopulation, and enhanced surveillance, but it underscored the vulnerability of even well-resourced poultry systems to incursions of velogenic NDV. Meanwhile, mesogenic and velogenic genotype V and VI strains continue to circulate endemically in parts of Mexico, Central America, and South America [2, 28].

Waterfowl play a critical but often underappreciated role in NDV epidemiology. Ducks and geese are generally considered natural reservoirs, typically remaining asymptomatic even when infected with strains highly lethal to chickens [25]. However, Dai et al. (2014) demonstrated that a duck-origin velogenic NDV (strain JSD0812) could cause clinical disease, neurologic signs, and mortality in experimentally infected ducks, particularly in young birds and specific breeds [25]. Infected ducks shed virus from the pharynx and cloaca for up to seven days, confirming their potential as active participants in viral transmission cycles. Furthermore, experimental co-infection studies have shown that NDV can interact with avian influenza viruses (AIV) and other respiratory pathogens in ducks and turkeys, with complex effects on shedding dynamics, clinical severity, and transmission efficiency [17, 21].

Vaccine-Driven Selection and the Need for Genotype-Matched Vaccines

A defining challenge in NDV epidemiology is the growing disconnect between the genotypes used in commercial vaccines (predominantly genotype II strains LaSota, B1, and F) and the genotypes circulating in the field (predominantly genotype VII, V, and VI). Although these classic vaccines have an exemplary safety record and provide robust protection against morbidity and mortality, they consistently fail to block viral replication and shedding, allowing virulent field strains to perpetuate in vaccinated populations [7, 16, 18-20, 36, 42]. Miller et al. (2013) demonstrated in controlled experiments that high levels of homologous antibodies induced by genotype VII-matched inactivated vaccines were significantly more effective at reducing shedding than heterologous (genotype II) antibodies, even when the latter were present at high titers [42]. Similarly, Kim et al. (2013) showed that chimeric LaSota viruses expressing the F protein from a genotype VII strain provided near-complete protection against shedding, while the parental LaSota vaccine did not [29]. The F protein was identified as the primary driver of this genotype-specific protective immunity [29]. These findings have catalyzed the development and licensing of genotype-matched live attenuated and inactivated vaccines in countries like China and Mexico, where targeted use has been associated with successful suppression of field virus circulation [20, 41]. Nonetheless, the continuous emergence of new sub-genotypes, the high cost of vaccine development, and the logistical difficulties of delivering cold-chain-dependent vaccines in resource-limited settings remain formidable obstacles [7, 20].

Genetic Markers of Epidemiological Surveillance

Surveillance for NDV has been greatly enhanced by the widespread adoption of molecular diagnostic tools, including conventional RT-PCR, real-time quantitative RT-PCR (rRT-PCR), and next-generation sequencing (NGS) [7, 40]. The WOAH-recommended target for genotyping is the complete open reading frame (ORF) of the fusion protein gene (1,662 nucleotides), which provides sufficient phylogenetic resolution to assign genotype and sub-genotype with confidence [2, 7, 12]. Sequence analysis of the F gene cleavage site is used as a proxy for pathotype prediction, although, as noted, it is not infallible in isolation. The integration of phylogenetic analysis with epidemiological metadata, including date of collection, geographic origin, host species, and vaccination history, has enabled the reconstruction of transmission networks and the identification of source populations during outbreaks [2, 10, 18]. Additionally, the use of curated databases and standardized genotyping pipelines, as advocated by the 2019 consortium, reduces inter-laboratory variability and facilitates global meta-analyses [2]. As NDV continues to evolve, sustained genomic surveillance at regional and global scales will be essential to detect emerging variants, assess antigenic drift, and guide timely updates to vaccination strategies.

Clinical Manifestations and Pathologic Mechanisms of NDV Infection

The clinical presentation of Newcastle disease virus (NDV) infection is a reflection of a complex interplay between viral virulence determinants, host immune status, and environmental factors. The disease, caused by virulent strains of avian paramyxovirus type 1 (APMV-1), is recognized globally as a devastating pathogen of poultry, with manifestations ranging from subclinical to rapidly fatal systemic illness, depending on the pathotype and host susceptibility [7, 19, 27]. The clinical signs are a direct consequence of the virus’s capacity to replicate in and damage a wide array of tissues, including the respiratory, gastrointestinal, neurological, and immune systems [20]. The severity of disease is primarily determined by the molecular configuration of the viral fusion (F) protein cleavage site, which dictates tissue tropism and systemic spread [23, 31]. However, it is now understood that virulence is a polygenic trait, modulated by regions of the F protein beyond the cleavage site, as well as contributions from the hemagglutinin-neuraminidase (HN) protein and other viral proteins [11, 23, 29].

Spectrum of Clinical Disease

NDV isolates are classified into five pathotypes based on clinical severity in chickens: lentogenic (avirulent), mesogenic (intermediate), and velogenic, which is further subdivided into velogenic viscerotropic and velogenic neurotropic forms [19, 28]. Lentogenic strains, such as LaSota and B1, typically cause only subclinical respiratory infections or mild respiratory signs in immunologically naïve birds, serving as the backbone for most live vaccines due to their safety profile [9, 13, 24]. Mesogenic strains, such as strain R2B, cause moderate respiratory distress, occasional nervous signs, and a drop in egg production, but mortality is generally low except in young or stressed birds [24]. The most economically devastating forms are the velogenic strains. Velogenic viscerotropic NDV (vvNDV) induces an acute, often peracute, illness characterized by high fever, profound depression, inappetence, and a rapid onset of severe respiratory distress (gasping, coughing). This is followed by profuse, greenish, watery diarrhea, reflecting the extensive hemorrhagic lesions in the gastrointestinal tract [18, 20, 36]. Mortality in fully susceptible, unvaccinated flocks can approach 100%, with death occurring within 2–6 days post-infection [10, 28]. Velogenic neurotropic NDV, while similarly lethal, presents with prominent neurological signs such as tremors, paralysis of the wings and legs, torticollis (twisted neck), and opisthotonos, often with less severe gastrointestinal involvement [10, 25, 28]. In adult laying hens, a sudden and dramatic drop in egg production, with the production of misshapen, thin-shelled, or shell-less eggs, is a hallmark sign [10, 27].

Histopathological Progression and Tissue Tropism

The pathologic cascade begins with viral entry into host cells. NDV enters cells via a dual mechanism: either by direct fusion with the plasma membrane at neutral pH or via a dynamin-dependent, low-pH-triggered endocytic pathway [30]. After replication in the epithelial cells of the upper respiratory tract and gut-associated lymphoid tissue, the virus disseminates systemically. The clinical progression is intricately linked to the virus's ability to cause profound damage to the lymphoid system. The bursa of Fabricius, spleen, thymus, and gut-associated lymphoid tissue (GALT) are primary targets. Infection leads to severe lymphoid depletion, necrosis, and atrophy of these organs, directly compromising the host’s ability to mount an effective adaptive immune response [27, 31, 35]. In the respiratory tract, gross lesions include congestion, hemorrhage, and fibrinonecrotic exudate in the trachea and lungs, often complicated by secondary bacterial infections such as Escherichia coli or Mycoplasma gallisepticum [37]. The gastrointestinal tract, particularly in vvNDV infections, exhibits characteristic hemorrhagic, necrotic ulcers on the lymphoid aggregates (Peyer’s patches and cecal tonsils), leading to the classic greenish diarrhea [18]. Neurological damage, seen in both viscerotropic and neurotropic forms, manifests as non-suppurative encephalomyelitis with neuronal necrosis, perivascular cuffing, and gliosis, explaining the motor dysfunction and paralysis [10].

Cellular and Molecular Pathologic Mechanisms

The tissue damage observed clinically is the culmination of a multi-faceted cellular response that the virus hijacks to facilitate its replication, often to the detriment of the host. A critical early event is the induction of the unfolded protein response (UPR). NDV infection activates all three branches of the UPR, PERK-eIF2α, ATF6, and IRE1α, in both avian and human cells [34]. The PERK-eIF2α pathway, while initially an attempt to halt translation and limit viral protein synthesis, is ultimately subverted. The downstream transcription factor CHOP is induced, which downregulates anti-apoptotic BCL-2/MCL-1 and promotes JNK signaling, leading to apoptosis. Simultaneously, the IRE1α pathway splices XBP1 mRNA, activating a transcriptional program that enhances the production of ER chaperones and ER-associated degradation (ERAD) components. This IRE1α activation also drives apoptosis and the secretion of pro-inflammatory cytokines through JNK signaling [34]. Crucially, the suppression of apoptosis or UPR impairs NDV replication, indicating that the virus requires these programmed death pathways for efficient progeny release [34].

Beyond apoptosis, NDV harnesses other forms of programmed cell death. Recent research has demonstrated that NDV can trigger ferroptosis, a non-apoptotic, iron-dependent form of cell death characterized by accumulation of lipid peroxides. This occurs through the p53-SLC7A11-GPX4 pathway, where NDV-induced nutrient deprivation and ferritinophagy (autophagic degradation of ferritin) release free iron, intensifying the Fenton reaction and lipid peroxidation [33]. This mechanism is particularly relevant in the context of NDV’s oncolytic properties, as it provides an alternative route to kill therapy-resistant cancer cells [6, 33].

A major driver of the systemic pathology is the "cytokine storm." NDV infection triggers a massive release of pro-inflammatory cytokines, including IL-1β, IL-6, and IFN-γ [31, 34-36]. The production of IL-1β is a central mediator of the inflammatory reaction and is induced via the NLRP3/caspase-1 inflammasome pathway in response to NDV RNA [35]. The high mobility group box 1 (HMGB1) protein, a damage-associated molecular pattern (DAMP), is also actively released from NDV-infected cells. HMGB1 acts as a potent inflammatory mediator, promoting the production of other cytokines through interactions with receptors such as RAGE, TLR2, and TLR4, thereby amplifying the inflammatory cascade and contributing to tissue damage and mortality [38]. The clinical significance of IL-1β and HMGB1 has been demonstrated, as neutralizing antibodies against these factors reduced fever and mortality in infected chickens [35, 38].

Metabolic Reprogramming and Immune Evasion

A hallmark of NDV infection is its ability to reprogram host cell metabolism to create an optimal environment for replication. NDV induces a metabolic shift from oxidative phosphorylation (OXPHOS) to aerobic glycolysis (the Warburg effect), a process that is otherwise characteristic of cancer cells. Mechanistically, NDV infection causes mitochondrial damage, generating elevated mitochondrial reactive oxygen species (mROS) and electron transport chain dysfunction [32]. This results in a depleted ATP pool, activating AMPK and initiating PINK1-PRKN-dependent mitophagy. Through this mitophagy, the virus targets and degrades the NAD+-dependent deacetylase SIRT3. The loss of SIRT3 leads to the stabilization of HIF1α, which then drives the transcriptional program promoting glycolysis [32]. This "warburg-like" effect is not merely a byproduct of infection but is critical for viral replication, as it provides necessary biosynthetic precursors and suppresses the host’s ability to mount an effective antiviral response [32, 43].

The host's primary antiviral defense, the type I interferon (IFN) response, is a major battleground during NDV infection. NDV is a potent inducer of IFN, largely through the detection of its long double-stranded RNA (dsRNA) replication intermediates by sensors like protein kinase R (PKR) and RIG-I [31, 44]. PKR activation leads to eIF2α phosphorylation, which inhibits global protein synthesis, thereby restricting viral replication [44]. However, virulent NDV strains have evolved countermeasures. The viral V protein and the newly characterized W protein are key antagonists of the interferon response [11, 31]. The W protein, which localizes to the nucleus due to a bipartite nuclear localization sequence, likely interferes with host gene expression to suppress antiviral signaling [11]. This intricate dynamic, where the virus triggers a potent IFN response but simultaneously blocks its downstream effects, dictates the course of infection, explaining the high virulence of certain strains [14, 31].

The interplay between the virus and the host’s stress and survival pathways is a final determinant of pathology. NDV-induced endoplasmic reticulum stress and mitochondrial dysfunction converge to activate autophagy [31, 32]. While autophagy can be a cellular survival mechanism to remove damaged organelles and pathogens, NDV co-opts this process to support its own replication. The PINK1-PRKN mitophagy pathway is directly utilized to degrade SIRT3, facilitating the metabolic shift described earlier [32]. This complex web of interactions, encompassing apoptosis, ferroptosis, metabolic reprogramming, and immune evasion, explains the profound and often rapid tissue damage observed in clinical NDV infections, from the hemorrhagic lesions in the gut to the necrotic foci in the spleen and the encephalitis in the brain [10, 31, 35]. The severity of disease is therefore a direct readout of the efficiency with which a particular NDV strain can orchestrate these pathologic pathways while simultaneously disarming the host’s defensive machinery.

Host Immune Response, Cytokine Dynamics, and Antagonistic Mechanisms

The host response to Newcastle disease virus (NDV) is a multifaceted and dynamic interplay between innate antiviral defenses, systemic inflammatory cascades, and sophisticated viral countermeasures. Central to NDV pathogenesis is the delicate balance between protective immunity and immunopathology; an overly robust or dysregulated response can culminate in the severe tissue damage and high mortality characteristic of velogenic strains [27, 31]. The outcome of infection, ranging from subclinical clearance to fatal disease, is dictated largely by the kinetics, magnitude, and composition of the cytokine response, the efficiency of programmed cell death pathways, and the capacity of the virus to subvert the host’s interferon (IFN) network. This section provides an exhaustive examination of these interconnected processes, drawing on recent molecular insights into NDV-host interactions.

1. Innate Immune Sensing and the Induction of the Interferon Response

The initial confrontation between NDV and the host occurs at the level of pattern recognition receptors (PRRs) that detect viral molecular signatures. NDV, a negative-sense single-stranded RNA virus, generates double-stranded RNA (dsRNA) intermediates during genome replication and transcription, which are potent pathogen-associated molecular patterns (PAMPs) [44]. These dsRNA species are recognized primarily by the cytoplasmic sensor protein kinase R (PKR) and the retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), including RIG-I and melanoma differentiation-associated protein 5 (MDA5) [31, 44]. In avian species, the RLR pathway is critical for triggering the downstream type I interferon (IFN) response. Activation of PKR by dsRNA leads to its autophosphorylation and subsequent phosphorylation of the eukaryotic translation initiation factor 2 alpha (eIF2α), which globally attenuates host and viral protein synthesis, thereby imposing a broad antiviral state [44]. Indeed, NDV infection has been shown to activate the PKR/eIF2α signaling cascade in a dose-dependent manner, independent of the pathotype, with both lentogenic (LaSota) and velogenic (Herts/33) strains inducing this response [44]. The importance of this axis is underscored by the observation that siRNA-mediated knockdown of PKR diminishes eIF2α phosphorylation and reduces IFN-β mRNA levels, leading to a marked increase in extracellular virus titers [44]. Conversely, direct phosphorylation of eIF2α or treatment with the phosphatase inhibitor okadaic acid impairs NDV replication, confirming that the PKR/eIF2α pathway constitutes a restrictive barrier to viral propagation [44].

Parallel to PKR activation, RIG-I and MDA5 engage the mitochondrial antiviral-signaling protein (MAVS), initiating a signaling cascade that culminates in the nuclear translocation of interferon regulatory factors (IRFs) and NF-κB, driving the expression of IFN-β and a multitude of proinflammatory cytokines [27, 31]. NDV is a notoriously potent inducer of type I IFNs, a property that has been exploited both for its oncolytic application and for understanding the basis of its host range restriction in humans [14, 27]. The magnitude of the IFN response is a key determinant of virulence; highly pathogenic strains have evolved mechanisms to dampen this induction, while lentogenic strains typically elicit a more transient and controlled IFN response [27, 31]. The resulting IFN molecules (IFN-α/β) act in an autocrine and paracrine manner, binding to the IFN-α/β receptor (IFNAR) and activating the Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway. This leads to the transcriptional upregulation of hundreds of interferon-stimulated genes (ISGs), including myxovirus resistance protein (Mx), 2'-5'-oligoadenylate synthetase (OAS), and interferon-induced transmembrane proteins (IFITMs), which collectively establish a cellular environment refractory to viral replication [27]. In chicken models, the expression levels of ISGs such as Mx have been correlated with resistance to NDV, and genome-wide association studies have identified loci on chromosome 1, including the ROBO2 gene, that modulate antibody response and potentially the inherent resistance to infection [48].

2. Cytokine Dynamics: The Inflammatory Cascade and Systemic Pathology

While the IFN response represents the front line of antiviral defense, the ensuing cytokine storm, a hyperinflammatory state characterized by the overproduction of interleukins, chemokines, and other mediators, is a hallmark of virulent NDV infection and a primary driver of the severe clinical signs associated with Newcastle disease [31, 35, 38]. The transition from a protective to a pathogenic immune response is orchestrated by a network of key cytokines, chief among them interleukin-1β (IL-1β), interleukin-6 (IL-6), and high mobility group box 1 (HMGB1).

IL-1β and the NLRP3 Inflammasome: IL-1β is a central mediator of inflammation, fever, and acute-phase responses. Infection with virulent NDV strains, such as the chicken/Guangdong/GM/2014 (GM) isolate, induces large quantities of IL-1β, and this excessive expression exacerbates systemic inflammatory damage [35]. Neutralization of IL-1β with specific antibodies significantly reduces body temperature and mortality in infected chickens, directly implicating this cytokine in the pathogenesis of severe ND [35]. Mechanistically, NDV-induced IL-1β production is critically dependent on the NLRP3/caspase-1 inflammasome axis. Overexpression of NLRP3 potentiates IL-1β expression, while pharmacological or genetic inhibition of NLRP3 or caspase-1 markedly suppresses its secretion [35]. Notably, the viral RNA itself is the activating PAMP; ultraviolet-inactivated virus fails to elicit IL-1β, whereas purified viral RNA is sufficient to induce the canonical NLRP3/caspase-1 pathway [35]. This indicates that endosomal or cytosolic sensing of NDV RNA, likely through TLRs or RLRs, triggers the assembly of the NLRP3 inflammasome, leading to caspase-1 activation, cleavage of pro-IL-1β, and the release of the mature, bioactive cytokine. The resultant IL-1β amplifies the inflammatory cascade, recruiting immune cells and promoting the production of downstream cytokines, thereby contributing to the disseminated intravascular coagulation, hemorrhagic lesions, and multi-organ failure observed in velogenic infections.

IL-6 and Acute-Phase Proteins: Interleukin-6 is another critical cytokine whose expression levels correlate closely with NDV virulence [31]. Velogenic strains provoke a more pronounced and sustained elevation of IL-6 compared to lentogenic strains, and this surge is associated with the induction of acute-phase proteins, fever, and metabolic dysregulation [31, 36]. In vaccination-challenge experiments, IL-6 levels are significantly higher in vaccinated birds that are subsequently challenged, reflecting the activation of the adaptive immune response, but in unvaccinated, challenged birds, the IL-6 response can become pathological [36]. The IL-6/STAT3 signaling axis is also a node for immunosuppressive feedback; NDV infection has been shown to activate STAT3, which in turn upregulates indoleamine 2,3-dioxygenase 1 (IDO1) and promotes the infiltration of myeloid-derived suppressor cells (MDSCs) into the tumor microenvironment in oncolytic settings [43]. This negative feedback loop, while limiting immune-mediated damage in acute infection, can paradoxically suppress antitumor immunity and highlights the dualistic nature of the cytokine response [43].

HMGB1 as a DAMP Amplifier: Beyond viral PAMPs, NDV infection triggers the release of damage-associated molecular patterns (DAMPs) from injured cells, most prominently HMGB1 [38]. HMGB1 is a nuclear protein that, upon passive release from necrotic cells or active secretion by stressed immune cells, functions as a potent proinflammatory mediator. NDV infection induces HMGB1 secretion in both avian (DF-1) and human (A549) cell lines, and this release is independent of virus replication efficiency [38]. Once in the extracellular milieu, HMGB1 binds to its cognate receptors, RAGE (receptor for advanced glycation end products, TLR2, and TLR4, to activate NF-κB and MAPK signaling pathways, including ERK1/2 and JNK [38]. This signaling cascade synergizes with PAMP-driven pathways to amplify the production of a wide array of proinflammatory cytokines (e.g., TNF-α, IL-8) and chemokines, thereby perpetuating the cytokine storm. Critically, in vivo neutralization of HMGB1 reduces the severity of pathological changes and inflammatory cytokine expression, increasing survival rates [38]. This underscores a role for DAMPs in driving the immunopathology of ND, independent of direct viral cytolysis.

The Cytokine Network in Vaccination and Co-infection: The dynamics of cytokine expression are also critical in shaping vaccine efficacy and the outcome of co-infections. Vaccination with genotype-matched vaccines, particularly those incorporating both hemagglutinin-neuraminidase (HN) and fusion (F) proteins, leads to elevated and more protective IL-6 and IFN-γ responses, which correlate with reduced viral shedding [29, 36]. Furthermore, co-infection models with NDV and avian influenza virus demonstrate that viral interference, mediated in part by the IFN response, alters the replication kinetics of both pathogens. In ducks and turkeys, sequential or simultaneous infection with lentogenic NDV and low-pathogenicity avian influenza virus results in decreased NDV shedding early in infection, followed by a rebound, suggesting a transient, IFN-mediated competitive effect for cellular resources [17, 21]. These findings illustrate how the temporal and spatial dynamics of the cytokine response can dictate the clinical trajectory of complex infections.

3. Programmed Cell Death Modalities as an Antiviral and Pathogenic Strategy

The host cell’s decision to undergo programmed cell death is a critical juncture in the NDV infection cycle. While apoptosis can serve as an antiviral mechanism to eliminate infected cells, NDV has evolved to manipulate cell death pathways, including apoptosis, autophagy, and ferroptosis, to facilitate its own replication, dissemination, and immune evasion [34, 39].

Apoptosis and the Unfolded Protein Response (UPR): NDV is a potent inducer of apoptosis in both avian and human tumor cells, a property central to its oncolytic potential [34, 45, 46]. The virus activates all three canonical branches of the UPR: the PERK-eIF2α, ATF6, and IRE1α pathways [34]. The PERK-eIF2α arm promotes the translation of the transcription factor CHOP (GADD153), which in turn downregulates the anti-apoptotic BCL-2 and MCL-1 proteins while simultaneously activating JNK and suppressing AKT pro-survival signaling [34]. Concurrently, the IRE1α branch mediates the splicing of XBP1 mRNA to produce XBP1s, a transcription factor that upregulates ER chaperones and components of ER-associated degradation (ERAD). Importantly, IRE1α also activates JNK signaling, which directly promotes both apoptosis and the secretion of proinflammatory cytokines [34]. This UPR-driven apoptosis is not merely a consequence of infection but is actively required for efficient NDV replication. Suppression of apoptosis or UPR signaling significantly impairs viral progeny production, while inhibition of the UPR with 4-PBA protects cells from NDV-induced cell death [34]. This suggests that NDV has evolved to subvert the host’s stress response, exploiting the apoptotic machinery to facilitate viral release and spread, a phenomenon that has been termed “virus-facilitated apoptosis” [34, 39].

Autophagy, Mitophagy, and Metabolic Reprogramming: NDV also modulates the autophagic machinery to support its replication niche. Infection induces a time-dependent shift from mitochondrial fusion to fission, accompanied by mitochondrial damage, elevated reactive oxygen species (mROS), and electron transport chain dysfunction [32]. The resultant increase in the AMP:ATP ratio activates AMP-activated protein kinase (AMPK), which in turn inhibits mTOR, leading to the induction of autophagy [32]. A specific form of selective autophagy, PINK1-PRKN-dependent mitophagy, is then engaged to eliminate damaged mitochondria. This process involves the ubiquitination of mitochondrial outer membrane proteins by PRKN, recruitment of the adaptor SQSTM1/p62, and the formation of autophagosomes that engulf dysfunctional organelles [32]. A key consequence of this mitophagy is the degradation of the mitochondrial deacetylase SIRT3. Loss of SIRT3 leads to the stabilization of hypoxia-inducible factor 1 alpha (HIF1A), which orchestrates a metabolic switch from oxidative phosphorylation (OXPHOS) to aerobic glycolysis (the Warburg effect) [32]. This metabolic reprogramming is advantageous for the virus, as it creates a cellular environment rich in glycolytic intermediates that can be channeled into biosynthetic pathways required for viral genome replication and assembly. Thus, NDV-induced mitophagy is a sophisticated mechanism to reshape host cell metabolism for optimal viral propagation.

Ferroptosis and Non-Apoptotic Cell Death: Beyond apoptosis and autophagy, NDV has been shown to trigger ferroptosis, an iron-dependent form of non-apoptotic cell death characterized by the accumulation of lipid peroxides [33]. In tumor cells, NDV infection activates ferroptosis through the p53-SLC7A11-GPX4 axis. The virus downregulates SLC7A11 (the xCT subunit of the cystine/glutamate antiporter), leading to cysteine deprivation, a decline in the intracellular antioxidant glutathione, and subsequent inactivation of the phospholipid hydroperoxidase GPX4 [33]. This results in unchecked lipid peroxidation and cell death. Furthermore, NDV induces ferritinophagy, the autophagic degradation of ferritin, which releases free ferrous iron (Fe²⁺) that potentiates the Fenton reaction, further amplifying the production of reactive oxygen species and lipid peroxides [33]. The induction of ferroptosis is a distinct mechanism through which NDV exerts its oncolytic effect, and it may also contribute to the inflammatory milieu by releasing DAMPs such as oxidized lipids and HMGB1, thereby bridging cell death modality with sterile inflammation.

4. Antagonistic Mechanisms: Viral Countermeasures Against Host Immunity

To establish productive infection, NDV has evolved a suite of non-structural and structural proteins that actively subvert the host’s antiviral arsenal. The primary targets of these antagonistic strategies are the IFN system, the apoptotic machinery, and the innate immune signaling cascades.

The V and W Proteins: Multifunctional IFN Antagonists: The NDV phosphoprotein (P) gene undergoes co-transcriptional editing, giving rise to a nested set of mRNAs that encode the structural P protein as well as accessory proteins V and W [11]. These proteins share an identical N-terminal domain but possess unique C-termini. The V protein is a well-characterized IFN antagonist in paramyxoviruses; it counters the host IFN response by interacting with the STAT proteins, particularly STAT1 and STAT2, preventing their phosphorylation and nuclear translocation, thereby blocking the JAK-STAT signaling cascade [31]. Additionally, the V protein can bind to MDA5, inhibiting its ability to activate the IFN-β promoter [31]. The expression of the V protein is a key determinant of virulence; viruses lacking V function are highly attenuated.

The W protein, for which expression was long suspected but only recently confirmed, adds another layer of complexity to NDV’s immune evasion strategy [11]. W-specific antisera have definitively demonstrated its expression during infection, and mass spectrometry has confirmed its incorporation into viral particles [11]. Remarkably, the W protein exhibits a bipartite nuclear localization sequence (NLS) within its unique C-terminal domain, leading to its prominent nuclear accumulation in infected cells [11]. This nuclear localization is functionally significant; mutation of the NLS relocalizes W to the cytoplasm and alters the dynamics of infection. While the precise targets of the W protein within the nucleus remain to be fully elucidated, it is hypothesized that it may interfere with the transcription or processing of host mRNAs, including those of ISGs, or possibly modulate the host cell cycle to create a more permissive environment for viral replication [11]. The differential editing frequency that governs the ratios of P, V, and W proteins likely provides the virus with a tunable mechanism to calibrate its level of immune antagonism according to the specific host and tissue environment.

Modulation of the UPR and Apoptosis for Viral Gain: As discussed above, NDV manipulates the UPR and apoptosis to its advantage. The virus does not simply tolerate these stress responses; it actively requires them for optimal replication. The CHOP-dependent downregulation of BCL-2 and activation of JNK are pro-viral, suggesting that NDV has evolved to “hijack” the host’s stress machinery to orchestrate a cell death program that facilitates viral release without triggering an overly robust inflammatory response that would be detrimental to the viral population [34]. Similarly, the induction of mitophagy and metabolic reprogramming is a controlled process that the virus directs, rather than a mere consequence of infection [32]. By degrading SIRT3 and promoting glycolysis, NDV ensures a steady supply of metabolic precursors for the synthesis of viral components, effectively commandeering the host’s biosynthetic capacity [32]. This represents a form of metabolic antagonism, wherein the virus re-wires the host cell to suppress mitochondrial functions that could otherwise contribute to antiviral signaling via mROS or the induction of intrinsic apoptosis.

Selective Replication and Immune Evasion in Tumor Cells: The oncolytic selectivity of NDV is intimately linked to its antagonistic mechanisms. Many cancer cells harbor defective IFN signaling pathways, making them unable to mount an effective antiviral state in response to NDV infection [6, 47]. In these cells, the virus’s own IFN-antagonistic proteins (V and W) can more effectively suppress the residual IFN response, allowing for unimpeded replication and oncolysis [47]. Conversely, normal cells with intact IFN signaling can restrict NDV replication, contributing to the virus’s remarkable safety profile in human clinical trials [6, 14]. This differential dependence on the IFN system underscores a fundamental principle of NDV pathogenesis: the success of the virus hinges on its ability to tilt the balance of the host immune response from effective clearance toward either productive infection (in permissive hosts or cells) or pathological inflammation (in susceptible avian hosts).

In summary, the host immune response to NDV is a highly orchestrated contest. The innate immune system rapidly deploys dsRNA sensors, the PKR pathway, and the type I IFN response to establish an antiviral state. However, the virus counters with a suite of accessory proteins that dismantle JAK-STAT signaling and manipulate the UPR and metabolic pathways. When this balance fails, as is often the case with velogenic strains in naive poultry, the resulting cytokine storm, driven by inflammasome activation, IL-1β, IL-6, and the DAMP HMGB1

Advanced Diagnostic Tools and Phylogenetic Classification Systems for NDV

The precise and rapid identification of Newcastle disease virus (NDV) isolates, coupled with a robust and universally accepted phylogenetic classification framework, forms the bedrock of effective epidemiological surveillance, outbreak control, and vaccine strain selection. The economic devastation wrought by Newcastle disease (ND) on global poultry production, recognized by the World Organisation for Animal Health (WOAH) as a notifiable disease, necessitates diagnostic and classification systems that are not only sensitive and specific but also capable of discerning subtle genetic and antigenic variations that can influence virulence, transmissibility, and vaccine escape [7, 28, 31]. The continuous evolution of NDV, driven by an error-prone RNA-dependent RNA polymerase, has resulted in a remarkable genetic diversity that renders traditional, phenotype-based characterization methods insufficient [2, 19]. This section provides an exhaustive analysis of the state-of-the-art diagnostic tools used to detect and characterize NDV, followed by a deep dive into the evolution and current consensus of phylogenetic classification systems, emphasizing their critical roles in global disease management.

The cornerstone of NDV diagnostics has historically been virus isolation in embryonated chicken eggs (ECE), a technique still considered the gold standard by many reference laboratories for its unparalleled sensitivity and ability to provide viable virus for further characterization [7, 19]. However, this method is inherently slow, labor-intensive, and requires high-level biosafety containment (typically BSL-2 or BSL-3 for velogenic strains), rendering it impractical for rapid, real-time outbreak response [7, 40]. To overcome these limitations, molecular diagnostic tools, particularly reverse transcription-polymerase chain reaction (RT-PCR) and its real-time quantitative variant (rRT-PCR), have become the frontline assays for NDV detection globally [40, 49, 50]. These assays target conserved regions of the genome, most frequently the fusion (F) protein gene or the matrix (M) protein gene, offering rapid sensitivity (often detecting as few as 10-100 viral copies) and high throughput [40, 50]. The inclusion of internal controls and multiplexing capabilities allows for the simultaneous detection of co-infecting pathogens, such as avian influenza virus (AIV) and infectious bronchitis virus (IBV), a common occurrence in commercial poultry operations [17, 21, 49]. The selection of sample type and transport conditions is critical for assay success; studies have demonstrated that flocked nylon swabs in brain heart infusion (BHI) broth, transported wet, significantly enhance the recovery and detection of viral RNA compared to other swabs and dry transport [50].

A quantum leap in diagnostic resolution has been achieved through genomic sequencing techniques, which have transitioned from targeted Sanger sequencing of the F gene’s cleavage site to comprehensive whole-genome sequencing (WGS) using next-generation sequencing (NGS) platforms [2, 7]. While the F protein cleavage site motif (e.g., ¹¹²R-R-Q-K-R-F¹¹⁷ for virulent strains) remains the primary molecular determinant of pathotyping [23, 31], WGS provides the granularity needed for high-resolution phylogenetic classification, identification of novel recombinants, and tracking of transmission pathways during outbreaks [2, 7, 10]. For instance, during the 2018-2019 California NDV outbreak, WGS of the isolated virulent NDV (vNDV) allowed for a definitive phylogenetic placement, distinguishing it from other North American isolates and revealing a close genetic relationship to strains from the Middle East, thereby informing targeted control measures [10]. Furthermore, NGS facilitates the detection of mixed infections and minor variant populations that can be missed by consensus Sanger sequencing, a critical feature given the quasispecies nature of RNA viruses [7]. These advanced sequencing data feed directly into the phylogenetic frameworks that govern our understanding of global NDV evolution.

The phylogenetic classification of NDV has undergone a significant paradigm shift, moving from subjective nomenclature systems to a standardized, objective, and globally accepted framework [2]. Historically, NDV isolates were classified based on pathotype (lentogenic, mesogenic, velogenic) and, later, by early genotyping schemes that often led to confusion due to overlapping criteria and inconsistent naming [2, 19]. The seminal work by Dimitrov, Afonso, and an international consortium of experts in 2019 established the current gold standard: an updated unified phylogenetic classification system that is based on complete F gene coding sequences (1662 nt) [2, 12]. This system defines two major classes: Class I, encompassing predominantly lentogenic viruses isolated from wild birds and live poultry markets, and Class II, which contains the vast majority of virulent strains and all vaccine strains (e.g., LaSota, B1, Hitchner B1) [2, 42]. Within Class II, the system objectively delineates genotypes (e.g., I, II, III, V, VI, VII, VIII, XII, XIII, XIV, XVIII, XXI) using a combination of phylogenetic topology, genetic distance analysis (with specific nucleotide distance thresholds), and branch support values [2, 20]. The most significant evolution in this system is the introduction of a dichotomous, hierarchical nomenclature for sub-genotypes (e.g., VII.1.1, VII.2), replacing the earlier alphanumeric designations (e.g., VIIa, VIIb, VIIc, VIId) that were inconsistently applied [2]. This new nomenclature, combined with rigorous sub-tree rooting guidelines, allows for the unambiguous tracking of virus ancestry and the dynamic addition of new sub-genotypes as they emerge, as seen with the recent identification of sub-genotype VII.2 strains in Asia and Africa [2, 12, 20].

The biological and epidemiological rationale for this classification system’s importance is profound. Genotype-matched vaccines have been shown to provide superior protection against virus replication and shedding compared to traditional, heterologous vaccines, a phenomenon directly linked to the genetic and antigenic distance between the vaccine strain and the circulating field virus [7, 16, 29, 36, 42]. For example, classical genotype II vaccines (LaSota) provide only partial protection or fail to block shedding against the currently predominant genotype VII vNDV, which is widespread in Asia, Africa, and the Middle East [16, 18, 20]. Studies have demonstrated that vaccination with a genotype VII-matched inactivated vaccine significantly reduces mortality, clinical signs, and, crucially, the titers of virus shed into the environment compared to birds vaccinated with a genotype II vaccine [16, 29, 36]. The primary immunogen responsible for this genotype-specific protection is the fusion (F) protein, as chimeric LaSota viruses expressing the F protein from a genotype VII strain conferred far greater reduction in shedding than those expressing the heterologous HN protein alone [29]. Therefore, the unified classification system is not merely an academic exercise; it is a practical tool for designing and deploying “vaccine-matching” strategies, which are essential for the eventual eradication of ND in endemic regions [20]. Despite these advances, challenges remain, including the high cost and technical expertise required for NGS, the need for continuous surveillance to identify emerging genotypes, and the critical requirement for global data sharing to maintain the accuracy and utility of the classification system [7, 12]. The integration of advanced diagnostics with this robust phylogenetic framework is essential for the ongoing fight against this devastating pathogen.

Vaccine Development, Control Strategies, and Economic Impact in Endemic Regions

The control of Newcastle disease (ND) in endemic regions represents one of the most formidable challenges facing global poultry health security. Despite the availability of vaccines for over six decades, virulent Newcastle disease virus (vNDV) continues to impose devastating economic losses and remains a notifiable pathogen to the World Organisation for Animal Health (WOAH, formerly OIE) due to its capacity for rapid transboundary spread [7, 27]. The persistence of ND in endemic areas, encompassing vast swathes of Asia, Africa, the Middle East, and parts of South America, reflects a complex interplay between viral evolution, suboptimal vaccination strategies, inadequate biosecurity infrastructure, and profound socioeconomic constraints that render conventional control paradigms insufficient [20, 28]. Addressing this multifaceted problem requires a paradigm shift that integrates next-generation vaccine platforms, genotype-matched immunogens, enhanced diagnostic surveillance, and context-specific economic interventions tailored to the realities of low- and middle-income countries.

Evolution of Vaccine Platforms: From Classic Strains to Reverse Genetics Systems

The historical cornerstone of ND control has been the use of live attenuated and inactivated vaccines derived from lentogenic (low-virulence) strains, predominantly LaSota and B1, both classified as genotype II viruses [24]. These vaccines have demonstrated an exemplary safety record and have been instrumental in reducing mortality from vNDV infections for more than 60 years [7, 20]. However, a critical limitation has become increasingly apparent: classical vaccines, while protective against clinical disease and death, fail to prevent infection, replication, and shedding of contemporary vNDV isolates, particularly those belonging to genotypes VII, VIII, and V that now dominate in many endemic regions [16, 18, 36, 42]. This phenomenon, often described as “vaccine breakthrough,” is not attributable to a failure of serological cross-reactivity per se, but rather to a quantitative insufficiency in the neutralizing antibody titers required to block viral replication at the mucosal level [42]. The World Health Organization (WHO) and Food and Agriculture Organization (FAO) have recognized such challenges as critical barriers to achieving sustainable control of high-impact veterinary diseases in resource-limited settings.

The advent of reverse genetics technology has fundamentally restructured the landscape of ND vaccine development [7, 9, 51]. This platform permits the precise genetic manipulation of the NDV genome, enabling the generation of recombinant viruses with tailored attenuation, enhanced immunogenicity, and the capacity to express heterologous antigens [13, 41, 51, 52]. One of the most significant advancements has been the creation of genotype-matched vaccines, wherein the fusion (F) and hemagglutinin-neuraminidase (HN) glycoproteins from a circulating virulent field strain are engineered into the backbone of a lentogenic vaccine virus, with the F protein cleavage site mutated to an avirulent motif [29]. This approach directly addresses the antigenic divergence between vaccine and field strains, which has been identified as a primary driver of vaccine failure in endemic settings [12, 18, 42]. For instance, studies comparing a genotype VII-matched chimeric vaccine (based on LaSota) against a conventional LaSota vaccine demonstrated that while both prevented mortality, only the genotype-matched vaccine significantly reduced the shedding of homologous vNDV challenge virus [16, 29]. Critically, this reduction in shedding was mediated predominantly by the F protein, underscoring its role as the principal target of protective immunity [29].

Genotype Matching, Antigenic Distance, and the Imperative for Regional Vaccine Customization

The genetic diversity of NDV has been formally classified into two classes (I and II) and at least 20 genotypes, with new genotypes and sub-genotypes continually emerging due to viral evolution and the ecological pressures imposed by vaccination [2, 20]. In endemic regions such as West Africa, Southeast Asia, and the Indian subcontinent, the circulation of genotypes VII, VIII, V, and VI has rendered traditional genotype II vaccines increasingly mismatched [12, 16, 18, 22]. This mismatch is not merely a phylogenetic curiosity; it has direct functional consequences. Amino acid substitutions at neutralizing epitopes on both the F and HN proteins of contemporary field isolates have been shown to reduce antibody recognition and neutralization capacity, allowing for productive infection even in vaccinated flocks [18, 42]. In China, for example, recent subgenotype VIId isolates exhibited only 81.9–88.1% amino acid identity in the F protein compared to vaccine strains, and cross-protection experiments confirmed that LaSota-vaccinated chickens were not fully protected against challenge [18]. Similarly, in Malaysia, a genotype VII isolate (IBS002) caused significant shedding in LaSota-vaccinated birds, whereas a recombinant genotype VII vaccine provided superior virological control [16].

The economic implications of this antigenic drift are profound. In countries like Nigeria, Indonesia, and Ethiopia, where backyard poultry production constitutes a critical livelihood and nutritional resource for millions, reliance on genotype II vaccines that permit asymptomatic shedding perpetuates a cycle of environmental contamination and recurrent outbreaks [1, 12, 26]. The inability of current vaccines to block transmission is particularly problematic in live bird markets (LBMs), which function as reservoirs for vNDV and facilitate its dissemination across geographic regions [22, 26]. Studies from Uganda and Ethiopia have documented the isolation of virulent NDV from apparently healthy poultry in LBMs, demonstrating that these venues serve as silent amplification nodes for the virus [22, 26]. The implementation of genotype-matched vaccines, which have been successfully deployed in some countries (e.g., China and Mexico for H5 avian influenza vectored by NDV), offers a rational pathway to break this transmission cycle [20, 41].

Novel Vaccine Platforms: Vectored, DNA, and Thermostable Formulations

Beyond genotype-matched live vaccines, several innovative platforms are being pursued to address the specific constraints of endemic regions. Recombinant NDV vectored vaccines represent a particularly versatile strategy, as the virus can be engineered to express protective antigens from multiple avian pathogens simultaneously, offering bivalent or multivalent protection [41, 51, 52]. For instance, recombinant NDV expressing the spike (S) protein of infectious bronchitis virus (IBV) has conferred complete protection against both virulent IBV and vNDV challenges in specific-pathogen-free chickens [51]. Similarly, NDV vectored vaccines expressing the hemagglutinin (HA) of highly pathogenic avian influenza (HPAI) have been licensed for use in poultry in China and Mexico, demonstrating the feasibility of this approach at a commercial scale [41]. The development of antigenically chimeric NDV vectors, which contain inserted foreign sequences that allow serological differentiation from wild-type NDV, also addresses the problem of pre-existing immunity in vaccinated flocks and enables DIVA (Differentiating Infected from Vaccinated Animals) strategies [41].

DNA vaccines encapsulating the NDV F gene in biodegradable nanoparticles have also shown considerable promise in experimental settings. Encapsulation in chitosan nanoparticles, poly(lactic-co-glycolic) acid (PLGA) nanoparticles, or CS-coated PLGA nanoparticles has been demonstrated to enhance delivery, protect the plasmid DNA from degradation, and induce robust cellular, humoral, and mucosal immune responses in chickens [53-55]. These platforms are particularly attractive for developing countries because they bypass the need for cold chain logistics, are stable under ambient temperatures, and can be produced at relatively low cost. The sustained release properties of nanoparticle-encapsulated DNA vaccines allow for prolonged antigen exposure, thereby improving immune memory [55].

Thermostable NDV vaccines represent another critical innovation for endemic regions where cold chain infrastructure is inadequate or absent. The genetic basis of NDV thermostability has been mapped to the hemagglutinin-neuraminidase (HN) protein, and reverse genetics has been used to engineer thermostable chimeric viruses by grafting the HN gene from thermostable strains (e.g., TS09-C) into the backbone of thermolabile vaccine strains (e.g., LaSota) [15]. The resulting recombinant viruses exhibited significantly enhanced thermostability, induced higher antibody responses, and conferred complete protection against vNDV challenge [15]. Such vaccines could be distributed without refrigeration, dramatically expanding access for smallholder farmers in remote rural areas.

Control Strategies: Integration of Vaccination, Biosecurity, and Surveillance

Effective ND control in endemic regions cannot be achieved through vaccination alone; it requires an integrated approach that combines immunization with enhanced biosecurity, active surveillance, and rapid diagnostic capacity [7, 28]. Biosecurity practices in many endemic areas remain severely inadequate, particularly in backyard production systems and LBMs where birds of various ages and health statuses are commingled [26, 28]. In Ethiopia, for example, a cross-sectional survey of LBMs revealed that the majority of poultry handlers lacked any awareness of disease transmission risks and did not implement basic disinfection measures [26]. Addressing these behavioral and structural deficits is essential to reduce the force of infection and to maximize the impact of vaccination programs.

The role of ducks and other waterfowl as asymptomatic reservoirs of vNDV adds another layer of complexity to control strategies [25]. Experimental infections have confirmed that duck-origin virulent NDV strains can cause disease in ducks, albeit with variable susceptibility across breeds and ages, and that infected ducks shed infectious virus from the pharynx and cloaca for up to seven days [25]. The co-circulation of NDV with other respiratory pathogens, such as avian influenza virus (AIV) and infectious bronchitis virus (IBV), further complicates the epidemiological picture, as co-infections can alter viral shedding dynamics and interfere with vaccine efficacy [17, 21, 49].

The development of rapid, sensitive, and field-deployable diagnostic assays is paramount for effective surveillance and early outbreak detection. Real-time reverse transcription PCR (rRT-PCR) has become the gold standard for NDV detection, but the extensive genetic diversity of the virus poses risks of primer-probe mismatch and false-negative results [7, 40, 49]. Next-generation sequencing (NGS) offers a powerful solution for unbiased detection and genotyping of NDV, even in mixed infections, but its cost and technical requirements currently limit its use to reference laboratories [7]. For endemic settings, a tiered diagnostic approach, combining rRT-PCR for initial screening with targeted sequencing for genotype confirmation, may represent the most pragmatic strategy. The WOAH Manual of Diagnostic Tests and Vaccines for Terrestrial Animals provides comprehensive guidelines for NDV diagnosis, and adherence to these standards is critical for harmonizing surveillance efforts globally.

Economic Impact in Endemic Regions: Quantifying Losses and Assessing Intervention Costs

The economic burden of ND in endemic regions is staggering, yet it remains poorly quantified due to the predominance of informal, smallholder production systems that are not captured in national agricultural statistics [20, 28]. In Indonesia, which has the largest poultry population in the world after China, ND is endemic and causes substantial economic losses that directly impact farmer livelihoods and community welfare [1]. In Nigeria, the genetic divergence between circulating NDV strains and vaccine strains has been linked to recurrent outbreaks despite high vaccination coverage, resulting in mortality rates that can exceed 80% in unprotected flocks [12]. The FAO has estimated that ND causes annual losses in the billions of US dollars globally, with the highest relative impact concentrated in low-income, food-deficit countries where poultry production is a critical component of household food security and income generation.

The economic impact of ND operates through multiple mechanisms: direct mortality losses, reduced egg production and weight gain in surviving birds, the cost of vaccines and their administration, the expense of outbreak response and culling, and the trade restrictions imposed by WOAH for notifiable outbreaks in previously free regions [27, 28]. In many endemic countries, the cost of vaccination is borne by smallholder farmers who often lack access to veterinary services, resulting in suboptimal coverage and improper vaccine handling that compromises efficacy [20]. The development of more effective, longer-lasting vaccines that can be administered less frequently and without cold chain dependence would dramatically reduce these transaction costs.

Importantly, the economic case for investing in improved ND control extends beyond the farm gate. Poultry production serves as a critical pathway out of poverty for rural households, providing a readily convertible source of protein and cash. Outbreaks of ND can push vulnerable families into destitution, erode household nutritional status, and perpetuate cycles of poverty. Epidemiologically informed economic analyses that account for the full societal costs of ND, including human health consequences from lost nutrition and the opportunity costs of foregone income, are urgently needed to advocate for increased investment from national governments and international donors. The World Bank and other development organizations have recognized the control of transboundary animal diseases as a global public good, and ND should be prioritized within this framework given its enormous burden on the world’s poorest poultry keepers.

References

[1] Dharmayanti N, Nurjanah D, Nuradji H, Suyatno T, Indriani R. Newcastle disease virus: the past and current situation in Indonesia. Journal of Veterinary Sciences. 2023. DOI: https://doi.org/10.4142/jvs.23022

[2] Dimitrov K, Abolnik C, Afonso C, Albina E, Bahl J, Berg M, et al.. Updated unified phylogenetic classification system and revised nomenclature for Newcastle disease virus. Infection, Genetics and Evolution. 2019. DOI: https://doi.org/10.1016/j.meegid.2019.103917

[3] Sun W, Liu Y, Amanat F, González-Domínguez I, McCroskery S, Slamanig S, et al.. A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nature Communications. 2021. DOI: https://doi.org/10.1038/s41467-021-26499-y

[4] Sun W, Leist S, McCroskery S, Liu Y, Slamanig S, Oliva J, et al.. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine. 2020. DOI: https://doi.org/10.1016/j.ebiom.2020.103132

[5] Sun W, McCroskery S, Liu W, Leist S, Liu Y, Albrecht R, et al.. A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines. 2020. DOI: https://doi.org/10.3390/vaccines8040771

[6] Burman B, Pesci G, Zamarin D. Newcastle Disease Virus at the Forefront of Cancer Immunotherapy. Cancers. 2020. DOI: https://doi.org/10.3390/cancers12123552

[7] Bello M, Yusoff K, Ideris A, Hair-Bejo M, Peeters B, Omar A. Diagnostic and Vaccination Approaches for Newcastle Disease Virus in Poultry: The Current and Emerging Perspectives. BioMed Research International. 2018. DOI: https://doi.org/10.1155/2018/7278459

[8] . Newcastle disease virus. CABI Compendium. 2022. DOI: https://doi.org/10.1079/cabicompendium.73357

[9] Bello M, Yusoff K, Ideris A, Hair-Bejo M, Jibril AH, Peeters B, et al.. Exploring the Prospects of Engineered Newcastle Disease Virus in Modern Vaccinology. Viruses. 2020. DOI: https://doi.org/10.3390/v12040451

[10] Dimitrov K, Ferreira H, Pantin-Jackwood M, Taylor T, Goraichuk I, Crossley B, et al.. Pathogenicity and transmission of virulent Newcastle disease virus from the 2018-2019 California outbreak and related viruses in young and adult chickens.. Virology. 2019. DOI: https://doi.org/10.1016/j.virol.2019.03.010

[11] Karsunke J, Heiden S, Murr M, Karger A, Franzke K, Mettenleiter T, et al.. W protein expression by Newcastle disease virus.. Virus Research. 2019. DOI: https://doi.org/10.1016/j.virusres.2019.02.003

[12] Bello M, Yusoff K, Ideris A, Hair-Bejo M, Peeters B, Jibril AH, et al.. Genotype Diversity of Newcastle Disease Virus in Nigeria: Disease Control Challenges and Future Outlook. Advances in Virology. 2018. DOI: https://doi.org/10.1155/2018/6097291

[13] Kim S, Samal S. Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines. Viruses. 2016. DOI: https://doi.org/10.3390/v8070183

[14] Schirrmacher V. Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!. Biomedicines. 2016. DOI: https://doi.org/10.3390/biomedicines4030016

[15] Wen G, Hu X, Zhao K, Wang H, Zhang Z, Zhang T, et al.. Molecular basis for the thermostability of Newcastle disease virus. Scientific Reports. 2016. DOI: https://doi.org/10.1038/srep22492

[16] Roohani K, Tan SW, Yeap S, Ideris A, Bejo M, Omar A. Characterisation of genotype VII Newcastle disease virus (NDV) isolated from NDV vaccinated chickens, and the efficacy of LaSota and recombinant genotype VII vaccines against challenge with velogenic NDV. Journal of Veterinary Sciences. 2015. DOI: https://doi.org/10.4142/jvs.2015.16.4.447

[17] Pantin-Jackwood M, Costa-Hurtado M, Miller PJ, Afonso C, Spackman E, Kapczynski D, et al.. Experimental co-infections of domestic ducks with a virulent Newcastle disease virus and low or highly pathogenic avian influenza viruses. Veterinary Microbiology. 2015. DOI: https://doi.org/10.1016/j.vetmic.2015.02.008

[18] Wang J, Liu W, Ren J, Tang P, Wu N, Wu H, et al.. Characterization of emerging Newcastle disease virus isolates in China. Virology Journal. 2015. DOI: https://doi.org/10.1186/s12985-015-0351-z

[19] Ganar K, Das M, Sinha S, Kumar S. Newcastle disease virus: Current status and our understanding. Virus Research. 2014. DOI: https://doi.org/10.1016/j.virusres.2014.02.016

[20] Hu Z, He X, Deng J, Hu J, Liu X. Current situation and future direction of Newcastle disease vaccines. Veterinary Research. 2022. DOI: https://doi.org/10.1186/s13567-022-01118-w

[21] Costa-Hurtado M, Afonso C, Miller PJ, Spackman E, Kapczynski D, Swayne D, et al.. Virus interference between H7N2 low pathogenic avian influenza virus and lentogenic Newcastle disease virus in experimental co-infections in chickens and turkeys. Veterinary Research. 2014. DOI: https://doi.org/10.1186/1297-9716-45-1

[22] Byarugaba D, Mugimba KK, Omony J, Okitwi M, Wanyana A, Otim MO, et al.. High pathogenicity and low genetic evolution of avian paramyxovirus type I (Newcastle disease virus) isolated from live bird markets in Uganda. Virology Journal. 2014. DOI: https://doi.org/10.1186/1743-422X-11-173

[23] Heiden S, Grund C, Röder A, Granzow H, Kühnel D, Mettenleiter T, et al.. Different Regions of the Newcastle Disease Virus Fusion Protein Modulate Pathogenicity. PLoS ONE. 2014. DOI: https://doi.org/10.1371/journal.pone.0113344

[24] Dey S, Chellappa MM, Gaikwad S, Kataria J, Vakharia V. Genotype Characterization of Commonly Used Newcastle Disease Virus Vaccine Strains of India. PLoS ONE. 2014. DOI: https://doi.org/10.1371/journal.pone.0098869

[25] Dai Y, Cheng X, Liu M, Shen X, Li J, Yu S, et al.. Experimental infection of duck origin virulent Newcastle disease virus strain in ducks. BMC Veterinary Research. 2014. DOI: https://doi.org/10.1186/1746-6148-10-164

[26] Mulisa DD, W/Kiros MK, Alemu RB, Keno M, Furaso A, Heidari A, et al.. Characterization of Newcastle Disease Virus and poultry-handling practices in live poultry markets, Ethiopia. SpringerPlus. 2014. DOI: https://doi.org/10.1186/2193-1801-3-459

[27] Kapczynski D, Afonso C, Miller PJ. Immune responses of poultry to Newcastle disease virus.. Developmental and Comparative Immunology. 2013. DOI: https://doi.org/10.1016/j.dci.2013.04.012

[28] Dzogbema K, Talaki E, Batawui K, Dao B. Review on Newcastle disease in poultry. . 2021. DOI: https://doi.org/10.4314/ijbcs.v15i2.29

[29] Kim S, Wanasen N, Paldurai A, Xiao S, Collins P, Samal S. Newcastle Disease Virus Fusion Protein Is the Major Contributor to Protective Immunity of Genotype-Matched Vaccine. PLoS ONE. 2013. DOI: https://doi.org/10.1371/journal.pone.0074022

[30] Sanchez-Felipe L, Villar E, Muñoz-Barroso I. Entry of Newcastle Disease Virus into the host cell: Role of acidic pH and endocytosis. Biochimica et Biophysica Acta. 2013. DOI: https://doi.org/10.1016/j.bbamem.2013.08.008

[31] Zhang D, Ding Z, Xu X. Pathologic Mechanisms of the Newcastle Disease Virus. Viruses. 2023. DOI: https://doi.org/10.3390/v15040864

[32] Gong Y, Tang N, Liu P, Sun Y, Lu S, Liu W, et al.. Newcastle disease virus degrades SIRT3 via PINK1-PRKN-dependent mitophagy to reprogram energy metabolism in infected cells. Autophagy. 2021. DOI: https://doi.org/10.1080/15548627.2021.1990515

[33] Kan X, Yin Y, Song C, Tan L, Qiu X, Liao Y, et al.. Newcastle-disease-virus-induced ferroptosis through nutrient deprivation and ferritinophagy in tumor cells. iScience. 2021. DOI: https://doi.org/10.1016/j.isci.2021.102837

[34] Li Y, Jiang W, Niu Q, Sun Y, Meng C, Tan L, et al.. eIF2α-CHOP-BCl-2/JNK and IRE1α-XBP1/JNK signaling promote apoptosis and inflammation and support the proliferation of Newcastle disease virus. Cell Death and Disease. 2019. DOI: https://doi.org/10.1038/s41419-019-2128-6

[35] Gao P, Chen L, Fan L, Ren J, Du H, Sun M, et al.. Newcastle disease virus RNA-induced IL-1β expression via the NLRP3/caspase-1 inflammasome. Veterinary Research. 2020. DOI: https://doi.org/10.1186/s13567-020-00774-0

[36] Sedeik M, Elbestawy A, El-shall N, El-Hack MEA, Saadeldin I, Saadeldin I, et al.. Comparative efficacy of commercial inactivated Newcastle disease virus vaccines against Newcastle disease virus genotype VII in broiler chickens. Poultry Science. 2019. DOI: https://doi.org/10.3382/ps/pey559

[37] Awad NF, El-Hamid MAA, Hashem Y, Erfan A, Abdelrahman BA, Mahmoud HI. Impact of single and mixed infections with Escherichia coli and Mycoplasma gallisepticum on Newcastle disease virus vaccine performance in broiler chickens: an in vivo perspective. Journal of Applied Microbiology. 2019. DOI: https://doi.org/10.1111/jam.14303

[38] Qu Y, Zhan Y, Yang S, Ren S, Qiu X, Rehamn ZU, et al.. Newcastle disease virus infection triggers HMGB1 release to promote the inflammatory response.. Virology. 2018. DOI: https://doi.org/10.1016/j.virol.2018.09.001

[39] Cuadrado-Castano S, Sánchez-Aparicio MT, García‐Sastre A, Villar E. The therapeutic effect of death: Newcastle disease virus and its antitumor potential. Virus Research. 2015. DOI: https://doi.org/10.1016/j.virusres.2015.07.001

[40] Mao Q, Ma S, Schrickel PL, Zhao P, Wang J, Zhang Y, et al.. Review detection of Newcastle disease virus. Frontiers in Veterinary Science. 2022. DOI: https://doi.org/10.3389/fvets.2022.936251

[41] Kim S, Samal S. Innovation in Newcastle Disease Virus Vectored Avian Influenza Vaccines. Viruses. 2019. DOI: https://doi.org/10.3390/v11030300

[42] Miller PJ, Afonso C, Attrache JE, Dorsey K, Courtney S, Guo Z, et al.. Effects of Newcastle disease virus vaccine antibodies on the shedding and transmission of challenge viruses.. Developmental and Comparative Immunology. 2013. DOI: https://doi.org/10.1016/j.dci.2013.06.007

[43] Meng G, Li B, Chen A, Zheng M, Xu T, Zhang H, et al.. Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma. British Journal of Cancer. 2019. DOI: https://doi.org/10.1038/s41416-019-0639-7

[44] Zhang S, Sun Y, Chen H, Dai Y, Zhan Y, Yu S, et al.. Activation of the PKR/eIF2α signaling cascade inhibits replication of Newcastle disease virus. Virology Journal. 2014. DOI: https://doi.org/10.1186/1743-422X-11-62

[45] Song H, Zhong L, He J, Huang Y, Zhao Y. Application of Newcastle disease virus in the treatment of colorectal cancer. World Journal of Clinical Cases. 2019. DOI: https://doi.org/10.12998/wjcc.v7.i16.2143

[46] Kalyanasundram J, Hamid A, Yusoff K, Chia S. Newcastle disease virus strain AF2240 as an oncolytic virus: A review.. Acta Tropica. 2018. DOI: https://doi.org/10.1016/j.actatropica.2018.04.007

[47] Tayeb S, Zakay‐Rones Z, Panet A. Therapeutic potential of oncolytic Newcastle disease virus: a critical review. Oncolytic Virotherapy. 2015. DOI: https://doi.org/10.2147/OV.S78600

[48] Luo C, Qu H, Ma J, Wang J, Li C, Yang C, et al.. Genome-wide association study of antibody response to Newcastle disease virus in chicken. BMC Genetics. 2013. DOI: https://doi.org/10.1186/1471-2156-14-42

[49] Naguib M, El-kady M, Lüschow D, Hassan KE, Arafa A, EL-ZANATY A, et al.. New real time and conventional RT-PCRs for updated molecular diagnosis of infectious bronchitis virus infection (IBV) in chickens in Egypt associated with frequent co-infections with avian influenza and Newcastle Disease viruses. Journal of Virological Methods. 2017. DOI: https://doi.org/10.1016/j.jviromet.2017.02.018

[50] Spackman E, Pedersen J, McKinley ET, Gelb J. Optimal specimen collection and transport methods for the detection of avian influenza virus and Newcastle disease virus. BMC Veterinary Research. 2013. DOI: https://doi.org/10.1186/1746-6148-9-35

[51] Shirvani E, Paldurai A, Manoharan VK, Varghese BP, Samal S. A Recombinant Newcastle Disease Virus (NDV) Expressing S Protein of Infectious Bronchitis Virus (IBV) Protects Chickens against IBV and NDV. Scientific Reports. 2018. DOI: https://doi.org/10.1038/s41598-018-30356-2

[52] Dey S, Chellappa MM, Pathak D, Gaikwad S, Yadav K, Ramakrishnan S, et al.. Newcastle Disease Virus Vectored Bivalent Vaccine against Virulent Infectious Bursal Disease and Newcastle Disease of Chickens. Vaccines. 2017. DOI: https://doi.org/10.3390/vaccines5040031

[53] Zhao K, Zhang Y, Zhang X, Li W, Shi C, Guo C, et al.. Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in chitosan nanoparticles. International Journal of Nanomedicine. 2014. DOI: https://doi.org/10.2147/IJN.S54226

[54] Zhao K, Zhang Y, Zhang X, Shi C, Wang X, Wang X, et al.. Chitosan-coated poly(lactic-co-glycolic) acid nanoparticles as an efficient delivery system for Newcastle disease virus DNA vaccine. International Journal of Nanomedicine. 2014. DOI: https://doi.org/10.2147/IJN.S70633

[55] Zhao K, Li W, Huang T, Luo X, Chen G, Zhang Y, et al.. Preparation and Efficacy of Newcastle Disease Virus DNA Vaccine Encapsulated in PLGA Nanoparticles. PLoS ONE. 2013. DOI: https://doi.org/10.1371/journal.pone.0082648